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Abstract
Background: There is significant evidence that severe tumor hypoxia may cause resistance to chemoradiotherapy
and promote metastatic spread in locally advanced carcinoma of the uterine cervix. Some clinical investigations have
suggested that high expression of hypoxia-inducible factor-1α (HIF-1α) and/or its target gene carbonic anhydrase IX
(CAIX) may be useful biomarkers of tumor hypoxia and poor outcome in cervical cancer. Here, we challenged this view
by investigating possible associations between HIF-1α expression, CAIX expression, fraction of hypoxic tissue, and lymph
node metastasis in experimental human tumors.
Methods: Tumors of two cervical carcinoma xenograft lines (CK-160 and TS-415) were included in the study.
Pimonidazole was used as a hypoxia marker, and tumor hypoxia, HIF-1α expression, and CAIX expression were
detected by immunohistochemistry. Metastatic status was assessed by examining external lymph nodes in the
inguinal, axillary, interscapular, and submandibular regions and internal lymph nodes in the abdomen and
mediastinum.
Results: Tissue regions staining positive for pimonidazole, HIF-1α, or CAIX were poorly colocalized, both in CK-160 and
TS-415 tumors. The expression of HIF-1α or CAIX did not correlate with the fraction of hypoxic tissue in any of the two
tumor lines. Furthermore, clinically relevant associations between HIF-1α or CAIX expression and lymph node metastasis
were not found.
Conclusion: Because significant associations between HIF-1α expression, CAIX expression, fraction of hypoxic tissue,
and incidence of lymph node metastases could not be detected in any of two preclinical models of human cervical
cancer, it is not realistic to believe that high expression of HIF-1α or CAIX can be useful biomarkers of tumor hypoxia
and poor outcome in a highly heterogeneous disease like cervical carcinoma.
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Background
Carcinoma of the uterine cervix is the fourth leading
cause of cancer-related death in women worldwide [1].
The prognosis is good for the earlier stages of the dis-
ease, but gets gradually worse with disease progression
[2]. In the western world, concurrent chemoradiotherapy
is the treatment of choice for locally advanced disease
[3]. Significant cure rates are achieved with concurrent
chemoradiotherapy, but at the expense of treatment-
related toxicities [3, 4].
Primary tumor volume, histology, lymph node status,
and stage of disease have been identified as important
prognostic factors in cervical carcinoma [3]. The out-
come of treatment can differ among individual patients
in the same prognostic group, possibly because of dif-
ferences in the physiological microenvironment of the
tumor tissue [5]. Severe abnormalities in the tumor
microenvironment, including low oxygen tension, ele-
vated interstitial fluid pressure, and acidification of the
extracellular space, have been shown to be associated
with locoregional treatment failure and poor disease-
free and overall survival rates [5–11]. Tumor oxygen
tension is the most studied microenvironmental parameter,
and there is strong evidence that severe hypoxia may cause
resistance to chemoradiotherapy and promote metastatic
dissemination in cervical carcinoma [12–15].* Correspondence: einar.k.rofstad@rr-research.no
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To improve the outcome of cervical cancer, reliable
biomarkers that can identify patients with aggressive
and treatment resistant tumors are needed [16]. Several
endogenous proteins have been suggested as potential
biomarkers of tumor hypoxia, including hypoxia-inducible
factor-1α (HIF-1α, the α subunit of the transcription factor
HIF-1) and downstream target genes of HIF-1 such as
vascular endothelial growth factor-A (VEGF-A), glucose
transporter-1, and carbonic anhydrase IX (CAIX) [17–20].
HIF-1α is degraded rapidly under normoxic conditions,
while under hypoxic conditions, HIF-1α is stabilized and
can dimerize with HIF-1β to form the HIF-1 protein com-
plex [21, 22]. Although HIF-1α is strongly regulated by
the oxygen tension in tumors and HIF-1 has multiple tar-
get genes promoting radiation resistance and malignant
progression [23], the potential of HIF-1α as a biomarker
of hypoxia and hypoxia-induced tumor aggressiveness in
cervical carcinoma is controversial [24–26]. High HIF-1α
expression correlated significantly with low oxygen ten-
sion and high level of binding of the exogenous hypoxia
marker pimonidazole in one study [25], whereas another
study showed no correlation between HIF-1α expression
and oxygen tension or hypoxic fraction [26]. Furthermore,
a significant correlation between the outcome of radiation
therapy and the expression of HIF-1α was reported in one
investigation [24], whereas HIF-1α expression was found
to have no significant prognostic impact in two other in-
vestigations [25, 26].
Among the target genes of HIF-1, CAIX seems to have
the greatest potential as a biomarker of tumor hypoxia
in cervical carcinoma [19, 27, 28]. CAIX appears to be
strictly regulated by hypoxia via HIF-1α [27] and shows
strong up-regulation in hypoxic regions of tumors of the
cervix [19]. Moreover, high level of CAIX in cervical tu-
mors has been shown to be associated with lymph node
metastasis [29] and to predict for poor overall and
metastasis-free survival rates after radiation therapy [19].
However, although significant correlations have been
found between CAIX expression and tumor hypoxia as
measured with polarographic electrodes [19], immuno-
histochemical comparisons of CAIX expression and pimo-
nidazole binding have yielded conflicting results [30, 31].
Olive et al. [30] compared the CAIX and pimonidazole im-
munostaining in tumor sections from 18 cervical cancer pa-
tients and observed excellent colocalization and a strong
correlation between the CAIX-positive and pimonidazole-
positive tissue fractions, whereas in a similar study involv-
ing 42 patients, Airley et al. [31] did not find a significant
correlation between CAIX expression and the level of
pimonidazole binding.
The contradictory reports on the potential of HIF-1α
and CAIX as endogenous markers of tumor hypoxia in
cervical carcinoma may have multiple explanations, in-
cluding different methods of measuring hypoxia, different
methods of detecting HIF-1α and CAIX expression, and
biological differences between the tumor cohorts sub-
jected to investigation [28]. Mayer et al. [32] have discour-
aged the use of the expression ‘endogenous hypoxia
markers’ and argue that the concept itself is unrealistic
in a heterogeneous clinical setting, primarily because
HIF-1α stabilization and the subsequent activation of
HIF-1 target genes may be influenced by hypoxia-
independent mechanisms.
Preclinical studies of human tumor xenografts have the
advantage to clinical investigations that the experimental
conditions can be controlled easily, and furthermore, that
multiple copies of a patient’s tumor can be examined. The
individual tumors of a xenograft line have the same genetic
background, but may have significantly different physio-
logical microenvironments due to the stochastic processes
involved in tumor angiogenesis. The purpose of the present
work was to challenge the view that HIF-1α and CAIX may
be useful biomarkers of tumor hypoxia and hypoxia-
induced tumor aggressiveness in cervical carcinoma by
searching for possible associations between HIF-1α ex-
pression, CAIX expression, fraction of hypoxic tissue,
and lymph node metastasis in tumors of two human
cervical carcinoma xenograft lines. Pimonidazole was used
as an exogenous hypoxia marker, and the CK-160 and TS-
415 lines were selected for the study because previous in-
vestigations have revealed that individual tumors of these




CK-160 and TS-415 human cervical carcinoma xeno-
grafts growing in adult female BALB/c nu/nu mice were
used as tumor models [33, 35]. Tumors were initiated
from cell lines cultured in RPMI-1640 (25 mmol/l
HEPES and l-glutamine) medium supplemented with
13 % bovine calf serum, 250 mg/l penicillin, and 50 mg/l
streptomycin. Approximately 5.0 × 105 cells in 10 μl of
Hanks’ balanced salt solution were inoculated in the
gastrocnemius muscle. Twenty CK-160 and 16 TS-415
tumors with volumes of 600–800 mm3 were included in
the study. Animal care and experimental procedures were
approved by our institution (Committee on Research Ani-
mal Care) and the Norwegian Animal Research Authority,
and were performed in accordance with the Interdisciplin-
ary Principles and Guidelines for the Use of Animals in
Research, Marketing, and Education (New York Academy
of Sciences, New York, NY, USA).
The CK-160 and TS-415 cell lines were established in
our laboratory from pelvic lymph node metastases of pa-
tients admitted to the Norwegian Radium Hospital for the
treatment of FIGO stage IIB squamous cell carcinoma of
the uterine cervix [33]. The metastatic pelvic lymph nodes
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were surgically excised from the patients prior to radiation
therapy. The use of metastatic lymph node tissue for estab-
lishing cervical carcinoma cell lines for experimental
purposes was approved by our institution (Committee
for Medical and Health Research Ethics). Written in-
formed consent was obtained from the donors of meta-
static lymph nodes.
Tumor hypoxia and expression of HIF-1α and CAIX
Hypoxic tumor tissue, HIF-1α expression, and CAIX
expression were detected by immunohistochemistry
[37]. Pimonidazole [1-[(2-hydroxy-3-piperidinyl)-pro-
pyl]-2-nitroimidazole], injected as described previously,
was used as an exogenous marker of tumor hypoxia
[38]. An anti-pimonidazole rabbit polyclonal antibody
(Professor Raleigh, University of North Carolina, Chapel
Hill, NC, USA), an anti-HIF-1α rabbit polyclonal antibody
(Abcam, Cambridge, UK), or an anti-CAIX rabbit poly-
clonal antibody (Abcam) was used as primary antibody. Di-
aminobenzidine was used as chromogen, and hematoxylin
was used for counterstaining. Histological sections were
prepared from three regions of each tumor. In each region,
adjacent sections were stained with hematoxylin and eosin
(HE) or immunostained for hypoxia, HIF-1α expression, or
CAIX expression. Hypoxic fraction (HFPim), HIF-1α
positive fraction (PFHIF-1α), and CAIX positive fraction
(PFCAIX), defined as the area fraction of the non-necrotic
tissue staining positive for pimonidazole, HIF-1α, or
CAIX, respectively, were assessed by image analysis [39].
Metastasis
Spontaneous metastasis was studied as described in de-
tail elsewhere [33, 36]. Briefly, after the primary tumor
was resected for immunohistochemical analyses, the
mice were examined for external lymph node metastases
in the inguinal, axillary, interscapular, and submandibu-
lar regions and internal lymph node metastases in the
abdomen and mediastinum. The presence of metastatic
growth in enlarged lymph nodes was confirmed by
histological examinations.
Statistical analysis
The Pearson product moment correlation test was used to
search for correlations between parameters. Statistical com-
parisons of data were carried out with the Student t test
when the data complied with the conditions of normality
and equal variance. Under other conditions, comparisons
were carried out by nonparametric analysis using the
Mann-Whitney rank-sum test. The Kolmogorov-Smirnov
method was used to test for normality. Probability values of
P < 0.05, determined from two-sided tests, were considered
significant. The statistical analysis was performed by using
the SigmaStat statistical software (SPSS Science, Chicago,
IL, USA).
Results
Low and high magnification images of the histological ap-
pearance of a representative CK-160 tumor and a repre-
sentative TS-415 tumor are presented in Figs. 1 and 2,
respectively. The images refer to a HE section and adja-
cent sections stained for pimonidazole, HIF-1α, or CAIX.
The tumors of both lines displayed considerable regions
with necrotic tissue and nests of parenchymal cells inter-
spersed with bands of connective tissue. Additionally, the
CK-160 tumors produced significant amounts of keratin,
frequently seen as secreted keratin pearls in central re-
gions of tumor cell nests and in necrotic regions.
In CK-160 tumors, pimonidazole-positive cells and
CAIX-positive cells were observed both adjacent to ne-
croses and in some regions consisting predominantly of
viable tissue, while strong staining for HIF-1α was seen
throughout the tumor tissue (Fig. 1a). Examinations at
high magnification revealed that pimonidazole and HIF-
1α were localized primarily in the keratinizing centers of
tumor cell nests, whereas CAIX showed an almost dia-
metrical staining pattern with expression only in the per-
iphery of these nests (Fig. 1b).
In TS-415 tumors, the pimonidazole staining pattern
was consistent with staining of chronically hypoxic tissue,
with bands of positive cells surrounding necrotic regions
and a few small foci of positive cells in tissue regions with-
out necroses (Fig. 2a). The expression of HIF-1α largely
mirrored this pattern (Fig. 2a), but HIF-1α-positive cells
did not extend as far from necrotic tissue as those positive
for pimonidazole (Fig. 2b). The expression of CAIX was
also associated with necrosis (Fig. 2a), but with positive
cells extending far from necrotic regions (Fig. 2b).
Quantitative analyses showed that HFPim, PFHIF-1α,
and PFCAIX differed substantially among individual
CK-160 tumors (Fig. 3a) and individual TS-415 tumors
(Fig. 3b). HFPim ranged from 0.23 to 0.53 (CK-160) and
from 0.08 to 0.39 (TS-415), and was significantly
higher in the CK-160 tumors than in the TS-415 tu-
mors (P < 0.0001). PFHIF-1α varied from 0.37 to 0.73
(CK-160) and from 0.03 to 0.18 (TS-415), and was also
significantly higher in the CK-160 tumors than in the
TS-415 tumors (P < 0.0001). In contrast, PFCAIX dif-
fered from 0.13 to 0.40 (CK-160) and from 0.16 to 0.46
(TS-415), and was significantly lower in the CK-160
tumors than in the TS-415 tumors (P = 0.012). Inter-
estingly, PFHIF-1α was significantly higher than HFPim
(P < 0.0001) and PFCAIX was significantly lower than
HFPim (P < 0.0001) in the CK-160 tumors, whereas in
the TS-415 tumors, PFHIF-1α was significantly lower
than HFPim (P < 0.0001) and PFCAIX was significantly
higher than HFPim (P = 0.0022). Furthermore, there
was no correlation between PFHIF-1α and HFPim, be-
tween PFCAIX and HFPim, or between PFHIF-1α and
PFCAIX in any of the lines (P > 0.05, Fig. 4).
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Lymph node metastases were detected in 10 of the
20 mice bearing CK-160 tumors and in 7 of the 16
mice bearing TS-415 tumors. In the CK-160 line, the
primary tumors of the metastasis-positive mice
showed significantly higher HFPim (P = 0.0002) and
significantly higher PFCAIX (P = 0.039) than those of
the metastasis-negative mice, but did not differ from
the primary tumors of the metastasis-negative mice in
PFHIF-1α (P > 0.05, Fig. 5a). The metastatic and nonme-
tastatic TS-415 tumors were not significantly different
in any of these three parameters (P > 0.05, Fig. 5b).
Moreover, none of the parameters were found to differ
between the metastatic and nonmetastatic tumors
when the data from the two tumor lines were analyzed
together (P > 0.05 for HFPim, PFHIF-1α, and PFCAIX).
Discussion
Tumor hypoxia represents a significant obstacle in the man-
agement of locally advanced carcinoma of the uterine cervix,
by increasing malignancy and inducing treatment resistance
[5–7, 12–15]. A major player in the hypoxia response is
HIF-1α, with its downstream target genes involved in cell
survival, metabolism, angiogenesis, and metastasis [17–23].
Based on a number of clinical studies, several investigators
have promoted the view that the expression of HIF-1α and
its target genes may be useful biomarkers of tumor hypoxia,
aggressiveness, and radiation resistance in cervical carcin-
oma [16, 18, 19, 24, 25, 29, 30]. In the present preclinical
study, we challenged this view by searching for correlations
between tumor hypoxia and the expression of HIF-1α and
CAIX in CK-160 and TS-415 cervical carcinoma xenografts.
Fig. 1 Histological appearance of CK-160 cervical carcinoma xenografts. Adjacent tumor sections stained with HE or immunostained for pimonidazole,
HIF-1α, or CAIX shown at low (a) and high (b) magnification. The high magnification images refer to the squared box in (a)
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A significant advantage of preclinical investigations
over clinical investigations is that the measurement
conditions can be kept unchanged during a study. A
major disadvantage of preclinical studies is that experi-
mental tumors may not necessarily be valid models of
human cancer. The CK-160 and TS-415 tumors used in
this study have some limitations as models of primary
tumors of the uterine cervix. First, the tumors were
transplanted ectopically to the gastrocnemius muscle,
and ectopic tumors may be inferior to orthotopic tumors
as models of cancer in humans. Second, the CK-160 and
TS-415 cell lines were established from lymph node me-
tastases, and the biological properties of lymph node me-
tastases may not be equal to those of primary tumors. It
should also be noticed that only the parenchyma of xeno-
grafted tumors is of human origin whereas the stroma is
recruited from the host and thus is of murine origin. Fur-
thermore, immune-deficient animals like BALB/c nu/nu
mice do not show a normal inflammatory response, and
the stromal conditions in tumors in such hosts may not
necessarily be representative for human tumors.
On the other hand, previous investigations have
revealed that CK-160 and TS-415 tumors retain sev-
eral biological properties of the donor patients’ pri-
mary tumors when transplanted intramuscularly in
BALB/c nu/nu mice, including response to radiation
therapy, histological appearance, and metastatic pat-
tern and propensity [33, 34]. These observations sug-
gest that CK-160 and TS-415 xenografts should be
useful models for investigating the potential of HIF-1α
and CAIX as biomarkers of hypoxia and metastasis in
tumors of the cervix.
Fig. 2 Histological appearance of TS-415 cervical carcinoma xenografts. Adjacent tumor sections stained with HE or immunostained for pimonidazole,
HIF-1α, or CAIX shown at low (a) and high (b) magnification. The high magnification images refer to the squared box in (a)
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Cervical carcinomas generally show significant intratu-
mor heterogeneity in oxygenation [6, 7, 13, 14], and onco-
genic mutations induced by fluctuating hypoxia or other
factors may lead to the development of multiple cell sub-
populations [16, 26]. Intratumor heterogeneity is a problem
in all biopsy-based methods being used for characterizing
malignant tumors and identifying hypoxia biomarkers. Dis-
tinctly different cell subpopulations were probably not a
problem in this study since the CK-160 and TS-415 tumors
were initiated from established cell lines showing no clonal
heterogeneity. However, both lines showed significant intra-
tumor heterogeneity in pimonidazole, HIF-1α, and CAIX
staining. To reduce the possibility of erroneous conclusions
caused by this heterogeneity, we subjected three different
regions of each tumor to immunostaining and histological
examinations.
The degrees of colocalization between pimonidazole-
positive tissue and HIF-1α- or CAIX-positive tissue were
poor in tumors of both lines. In the CK-160 tumors,
PFHIF-1α was higher and PFCAIX was lower than HFPim,
whereas PFHIF-1α was lower and PFCAIX was higher than
HFPim in the TS-415 tumors. Furthermore, HFPim did not
correlate with PFHIF-1α or PFCAIX in any of the tumor
lines. Because HIF-1α and CAIX are poor biomarkers of
Fig. 3 Pimonidazole and endogenous hypoxia markers. Tissue area fraction staining positive for pimonidazole, HIF-1α, or CAIX in CK-160 (a) and
TS-415 (b) cervical carcinoma xenografts. Points, individual tumors; horizontal lines, mean values
Fig. 4 Endogenous hypoxia markers and tumor hypoxia. PFHIF-1α versus HFPim, PFCAIX versus HFPim, and PFHIF-1α versus PFCAIX for CK-160 (a) and TS-415
(b) cervical carcinoma xenografts. Points, individual tumors
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hypoxia in xenografted tumors having the same genetic
background but differing in the extent of hypoxia, it is
unlikely that HIF-1α and CAIX can be useful bio-
markers of hypoxia in the clinical setting. Our study
thus provides strong support to the view of Mayer et al.
[32] that HIF-1α and its target genes should not be re-
ferred to as endogenous hypoxia markers.
Lack of correlation between the extent of pimonidazole
staining and the extent of HIF-1α or CAIX staining in cer-
vical carcinoma may be a consequence of both tumor-
specific conditions and tumor-independent mechanisms.
The tumor-independent mechanisms include differences
in the duration and level of hypoxia required for forma-
tion of pimonidazole adducts and expression of HIF-1α
and CAIX proteins as well as differences in the half-lives
of the adducts and the proteins [40, 41]. Moreover, the ex-
tent of HIF-1α and CAIX staining can be influenced by
the proliferation status of the hypoxic tumor cells [40] and
their metabolic and physiological microenvironments, in-
cluding the level of reactive oxygen and nitrogen species,
lowered extracellular pH and glucose and bicarbonate
deprivation, and the concentrations of some growth fac-
tors and cytokines [28, 32, 41, 42]. The fact that significant
correlations between HFPim and PFHIF-1α or PFCAIX were
not found in any of the two tumor lines included in the
present study underscores that the influence of tumor-
independent conditions is substantial.
The tumor-specific conditions include genetic changes
leading to stabilization of HIF-1α under normoxic condi-
tions, alterations of the HIF-1α degradation pathway, and
activation of HIF-1 target genes by hypoxia-independent
mechanisms [28, 32]. Several relevant genetic changes have
been identified, including loss of function of tumor sup-
pressor genes, for example the von Hippel-Lindau gene,
and gain of function of oncogenes leading to PI3K/
AKT/mTOR activity [43]. The importance of tumor-
specific mechanisms is underscored by the observation
that the ratios of PFHIF-1α and PFCAIX to HFPim were
fundamentally different in CK-160 and TS-415 tumors.
The differences in the ratios of PFHIF-1α and PFCAIX to
HFPim between the CK-160 and TS-415 lines reflected that
the tumors of these lines showed fundamentally different
staining patterns. The TS-415 tumors showed a perinecro-
tic staining pattern consistent with the classical view that
HIF-1α is stabilized in hypoxic tissue and induces CAIX
expression. The CK-160 tumors, in addition to showing a
perinecrotic staining pattern, also showed staining in tis-
sue regions far from necroses. Typically, the keratinizing
Fig. 5 Endogenous hypoxia markers and tumor metastasis. HFPim, PFHIF-1α, or PFCAIX in metastatic and nonmetastatic CK-160 (a) and TS-415 (b)
cervical carcinoma xenografts. Points, individual tumors; horizontal lines, mean values
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centers of the cellular nests in CK-160 tumors showed sig-
nificant staining for pimonidazole and HIF-1α, whereas a
diametrical staining pattern was seen for CAIX with posi-
tive staining primarily in the peripheral layers of the nests.
This staining pattern resembles the hypoxia staining pat-
tern observed in moderately differentiated squamous cell
carcinomas of the uterine cervix in humans [44–47]. In
these clinical studies, positive staining for pimonidazole
and the differentiation marker involucrin was seen primar-
ily in the central regions of tissue nests [44, 45], whereas
positive staining for the hypoxia-inducible proteins metal-
lothionein (MT) and VEGF-A was detected primarily in
the peripheral regions of the nests [46, 47]. These observa-
tions led to the suggestion that the differentiation of hyp-
oxic cells in cervical carcinomas exerts collateral control
on gene expression whereby the expression of hypoxia-
inducible proteins like MT and VEGF-A is suppressed
[45, 46]. In accordance with this suggestion, the
localization of CAIX in CK-160 tumors indicates that
the transcriptional status of CAIX is also altered by
differentiation.
Some clinical investigations have revealed that high
expression of HIF-1α and/or CAIX may be associated
with high incidence of lymph node metastases and
poor metastasis-free survival rates in cervical cancer
patients treated with radiation therapy [17, 19, 24, 29].
These observations have led to the hypothesis that
HIF-1α and CAIX may be useful biomarkers of the
outcome of locally advanced cervical carcinoma even
though the expression of these proteins may not be
strongly related to the extent of tumor hypoxia. The
present study does not support this view. First, previ-
ous investigations have revealed that lymph node me-
tastasis is associated with extensive hypoxia in CK-160
xenografts [33, 35], and this was confirmed in the
study reported here. PFHIF-1α was not associated with
lymph node metastasis in CK-160 tumors, whereas
PFCAIX was slightly higher in the metastatic than in the
nonmetastatic tumors, but did not discriminate as well
as HFPim. Second, there was no association between
HFPim and lymph node metastasis in TS-415 tumors,
in accordance with previous investigations [33, 36].
The metastatic and nonmetastatic TS-415 tumors did
not differ significantly in either PFHIF-1α or PFCAIX, but
both PFHIF-1α and PFCAIX tended to be higher in the
metastasis-negative than in the metastasis-positive tu-
mors, in contrast to the hypothesis described above.
Furthermore, neither PFHIF-1α nor PFCAIX was found to
be associated with lymph node metastasis when the
data from the CK-160 and TS-415 tumors were pooled.
Taken together, these observations suggest that high
expression of HIF-1α or CAIX cannot be clinically use-
ful biomarkers of poor outcome in squamous cell car-
cinoma of the uterine cervix.
Conclusions
The staining patterns of pimonidazole, HIF-1α, and
CAIX in CK-160 tumors differ from the corresponding
staining patterns in TS-415 tumors, and there is no cor-
relation between HFPim and PFHIF-1α or PFCAIX in any of
these human cervical carcinoma xenograft lines. More-
over, lymph node metastasis is not a result of high ex-
pression of HIF-1α or CAIX in CK-160 and TS-415
tumors. The individual tumors of a xenograft line have
identical genetic background in contrast to individual tu-
mors in cervical cancer patients, and consequently, the
observations reported here show that it is highly unlikely
that the expression of HIF-1α or CAIX can be useful
biomarkers of tumor hypoxia and/or outcome of chemo-
radiotherapy in locally advanced cervical carcinoma.
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